These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34783355)

  • 1. Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic.
    Patoulias D; Papadopoulos C; Zografou I; Katsimardou A; Imprialos K; Stavropoulos K; Tranidou A; Karagiannis A; Doumas M
    Kardiol Pol; 2022; 80(1):80-82. PubMed ID: 34783355
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.
    Patoulias D; Papadopoulos C; Boulmpou A; Doumas M
    Diabetes Obes Metab; 2021 Jul; 23(7):1696-1700. PubMed ID: 33606909
    [No Abstract]   [Full Text] [Related]  

  • 3. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021).
    Dashora U; Gregory R; Winocour P; Dhatariya K; Rowles S; Macklin A; Rayman G; Nagi D; Whitehead K; Beba H; De P; Patel DC;
    Clin Med (Lond); 2021 May; 21(3):204-210. PubMed ID: 34001571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
    Koufakis T; Metallidis S; Zebekakis P; Ajjan RA; Kotsa K
    J Diabetes Sci Technol; 2020 Jul; 14(4):745-747. PubMed ID: 32486846
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?
    Patoulias D; Papadopoulos C; Kassimis G; Doumas M
    Kardiol Pol; 2021; 79(9):1048-1049. PubMed ID: 34292565
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study.
    Patoulias D; Toumpourleka M; Katsimardou A; Zografou I; Stavropoulos K; Imprialos K; Karagiannis A; Doumas M; Papadopoulos C
    Kardiol Pol; 2022; 80(6):696-698. PubMed ID: 35445742
    [No Abstract]   [Full Text] [Related]  

  • 8. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
    Jacob L; Rickwood S; Rathmann W; Kostev K
    Diabetes Obes Metab; 2021 Apr; 23(4):910-915. PubMed ID: 33319440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Author's reply.
    Terlecki M; Wojciechowska W; Klocek M; Kania M; Małecki M; Grodzicki T; Rajzer M
    Kardiol Pol; 2021; 79(9):1050-1051. PubMed ID: 34292566
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus.
    Tan K; Chow WS; Leung J; Ho A; Ozaki R; Kam G; Li J; Choi CH; Tsang MW; Chan N; Lee KK; Chan KW
    Hong Kong Med J; 2019 Aug; 25(4):312-319. PubMed ID: 31416990
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
    Giugliano D; Longo M; Caruso P; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2021 Jul; 23(7):1672-1676. PubMed ID: 33710721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 inhibitors and hematopoiesis.
    Yaribeygi H; Maleki M; Nasimi F; Butler AE; Jamialahmadi T; Sahebkar A
    J Cell Physiol; 2022 Oct; 237(10):3778-3787. PubMed ID: 35951776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    Bielka W; Przezak A; Pawlik A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices.
    Patoulias D; Doumas M; Papadopoulos C
    Am J Cardiol; 2022 Jun; 172():169-170. PubMed ID: 35382927
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.
    Katsiki N; Gómez-Huelgas R; Mikhailidis DP; Pérez-Martínez P
    Int J Clin Pract; 2021 Nov; 75(11):e14833. PubMed ID: 34510676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter type-2 inhibitors: is the message getting through? A reply.
    Nathanson M
    Anaesthesia; 2019 May; 74(5):680. PubMed ID: 30957885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.